Acusphere (ACUS) Osake Kurssi

Acusphere Inc is primarily active in the pharmaceutical industry.

The main competitors of Acusphere Inc in the market are Company X, Company Y, and Company Z.

Acusphere Inc, a pharmaceutical solutions company, has an extensive history and background. Established in 1993, Acusphere focused on developing improved therapies through its proprietary technology platform. The company gained recognition for its expertise in manufacturing and formulating microsphere-based drugs. Acusphere was dedicated to addressing unmet medical needs and improving treatment options. While experiencing various milestones and advancements in medical research, the company unfortunately faced financial challenges and ultimately filed for bankruptcy in 2013. Acusphere's legacy remains as a pioneer in microsphere drug delivery, leaving behind a lasting impact on the pharmaceutical industry.

Acusphere Inc has achieved several significant milestones throughout its history. Notably, the company successfully developed and received FDA approval for its lead product candidate, Imagify, a cardiovascular diagnostic imaging agent. Acusphere Inc also entered into partnerships and collaborations with reputable pharmaceutical companies, which enabled further research and development opportunities. Additionally, the company has demonstrated its commitment to advancing healthcare by conducting clinical trials and securing patents to protect its innovative technologies. The continuous pursuit of innovation and the successful commercialization of its products have positioned Acusphere Inc as a prominent player in the pharmaceutical industry.

Acusphere Inc is primarily present in the United States.

Acusphere Inc represents values of innovation, commitment, and excellence in the field of healthcare. With a strong corporate philosophy focused on developing breakthrough technologies, Acusphere strives to enhance patient care and improve treatment options. The company prioritizes extensive research and development to create cutting-edge solutions that address unmet medical needs. Acusphere Inc consistently embraces collaboration within the scientific community to advance knowledge and achieve meaningful results. By upholding integrity and accountability, Acusphere is dedicated to providing safe and effective products that make a positive impact on patients' lives.

Nykyisellä valuuttakurssilla Acusphere-osake noteerataan hintaan 0,00 EUR (0,00 USD).

Acusphere Inc is a leading company in the production of microencapsulated drugs and diagnostic products. The company was founded in 1993 and is based in Watertown, Massachusetts. Acusphere is known for its nano- and microparticulate technologies. The business model of Acusphere focuses on the development and marketing of therapeutic and diagnostic products, with a focus on the treatment of heart diseases and other serious medical conditions. Acusphere's innovative technology encapsulates drugs in tiny particles, allowing for more effective delivery into the body. The active ingredients can be released in a targeted and controlled manner. One of Acusphere's central products is Imagify, a diagnostic agent for duplex sonography used for detecting blocked heart arteries. Imagify is particularly suitable for patients who are contraindicated for the usual method, Xenon-133 myocardial scintigraphy. It is the first non-invasive diagnostic agent for coronary heart disease based on microencapsulated perfluorocarbons. The company has developed AV002, a topical, microencapsulated version of the Kortexin antidepressant for treating rosacea. AV002 is an innovative method as it achieves rapid and long-lasting local effects while only minimally entering the systemic circulation. The drug is currently in phase IIa study. In addition to therapeutic and diagnostic products, Acusphere also develops products based on nano- and microparticulate technologies. The company holds patents on a wide range of technologies and treatment methods, including the production of micro- and nanoparticles and the manufacture and application of emulsions. Acusphere is a publicly traded company listed on NASDAQ under the ticker symbol ACUS in 2000. The company has a strong position in particle technology and experienced leaders to further expand and lead the company. Acusphere's business model relies on strong research and development to develop diagnostic and therapeutic products that can improve the lives of patients worldwide. The company closely collaborates with industry and academic partners to optimize and improve its technologies and products. Acusphere is committed to making a contribution to healthcare and the medical industry.

Liikevaihtoa ei voida laskea Acusphere:lle tällä hetkellä.

Voittoa ei voida laskea Acusphere:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Acusphere:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Acusphere:lle tällä hetkellä.

Acusphere:n Eulpool-laatuscore on 2/10.

Acusphere:n ISIN on US00511R8549. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Acusphere:n WKN on A1JTPA. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Acusphere:n ticker on ACUS. Tämä pörssinoteeraus käytetään Acusphere-osakkeiden kauppaan pörssissä.